Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
7
Next >
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
November 05, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
November 01, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
November 01, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
October 25, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca and Bob Harper Unveil the Survivors Have Heart Second Chance Portraits to Change the Face of Heart Attack Survivorship
October 21, 2021
From
AstraZeneca
Via
Business Wire
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
October 20, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
October 15, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
October 08, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
October 05, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
October 04, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
September 27, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
September 24, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
September 18, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
September 17, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
September 17, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
September 09, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
September 09, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season
August 31, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
August 20, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2
August 09, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
August 02, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
July 23, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
July 08, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
June 25, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Front-line Setting
June 07, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years
June 04, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
June 03, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
May 19, 2021
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.